Take Action

Newsroom

Filter By:
This safety-net program is failing many vulnerable patients
August 11, 2021
Axios
The 340B Program Soared to $38 Billion in 2020—Up 27% vs. 2019
June 16, 2021
Drug Channels
Biden Budget Offers Potential Oversight Tool on 340B Program
June 11, 2021
Citizens Against Government Waste
Summit: 340B an out-of-control train
May 26, 2021
BioWorld
New Report Exposes Extreme Profit Retained from 340B Program by Covered Entities, Particularly for Oncology Medicines

Today, the Alliance for Integrity and Reform of 340B (AIR340B) released a new report by Health Capital Group that uncovered significant growth in sales within the 340B Drug Pricing Program, including a near 200% increase in hospital participation in the program over the last decade. The question that remains is whether this growth has benefited patients.

“This new report is further evidence that the 340B program has become a lucrative revenue stream for disproportionate share hospitals and their contract pharmacies as a result of lax oversight and dismal transparency requirements. The data, obtained through the Freedom of Information Act, are proof of how difficult it is to ensure the vulnerable and uninsured communities the program is intended to support are benefiting from this exponential growth. At a minimum, greater oversight, transparency, and accountability should be required of these bad stewards of the program so we can ensure 340B is working for patients,” said former Illinois Congressman and AIR340B Spokesman Bob Dold.

May 26, 2021
New Report Exposes Extreme Profit Retained from 340B Program by Covered Entities, Particularly for Oncology Medicines
“340B Drug Discount Program Should Be on GAO’s High-Risk List”
April 2, 2021
RealClearHealth
New Poll: 86% of Voters Agree 340B Needs to Work Better for Patients

Today, the Alliance for Integrity and Reform of 340B (AIR340B) released a new poll conducted by Morning Consult that found a majority of those surveyed agreed the 340B Drug Pricing Program needs fixes to better serve the most vulnerable patients.

“The findings from this new poll are a stark reminder of the work we must do to save the 340B program – most importantly, to support the vulnerable and low-income communities that rely on it to help them access their medications. Through greater transparency, accountability, and oversight of the program, we can get 340B back on track so it fully benefits patients,” said former Illinois Congressman and AIR340B Spokesman Bob Dold.

March 30, 2021
“Congress Must Ensure Patients, Not Corporations, Benefit from 340B Drug Program”
January 25, 2021
Times of San Diego